Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D 2 receptors linked to adenylate cyclase

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 3, 2002, Pages 1166-1178

  Mottola, David M ^a   Kilts, Jason D ^a   Lewis, Mechelle M ^b   Connory, Hilary S ^c   Walker, Q David ^d   Jones, Sara R ^a   Booth, Raymond G ^e   Hyslop, Deborah K ^c   Piercey, Monford ^a   Wightman, R Mark ^d   Lawler, Cindy P ^a   Nichols, David E ^b   Mailman, Richard B ^c  

^a Departments of Psychiatry Pharmacology Chemistry and Medicinal Chemistry   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d PFIZER INC   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; CYCLIC AMP; DIHYDREXIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; FORSKOLIN; POSTSYNAPTIC RECEPTOR; PROLACTIN; QUINPIROLE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HYPOPHYSIS; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; TISSUE SLICE;

ADENYLATE CYCLASE; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; INJECTIONS, SUBCUTANEOUS; MALE; PHENANTHRIDINES; PITUITARY GLAND; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SYNAPTIC MEMBRANES;

EID: 0036260826     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.3.1166     Document Type: Article

References (78)

1. Lasting effects of dopamine receptor agonists upon striatal dopamine release in free-moving rats: An in vivo voltammetric study
2. 3-preferring ligands act at synthesis modulating autoreceptors
3. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
4. 2 receptors
5. 2 receptor mRNA
6. 1 full agonist
7. 1 dopamine receptor ligands
8. s
9. Midbrain dopamine system electrophysiological functioning: A review and new hypothesis
10. 3H]dihydroergocryptine binding with the dopaminergic control of prolactin release
11. 2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system
12. Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity. I. Review of the evidence
13. Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations
14. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: Dependence on extracellular dopamine
15. Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: Single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
16. 1 dopamine receptor agonist
17. 1 dopamine receptor mRNA in brain supports a role in cognitive, affective and neuroendocrine aspects of dopaminergic neurotransmission
18. Dopamine receptors: Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum
19. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
20. LA receptor
21. 2 receptor directs specificity of coupling to G-proteins
22. 1 receptor by several muscarinic ligands
23. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis
24. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats
25. Dopamine receptors and brain function
26. The PACAP receptor: Generation by alternative splicing of functional diversity among G protein-coupled receptors in nerve cells
27. Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor
28. Multiple receptors for dopamine
29. Detection of dopamine overflow and diffusion with voltammetry in slices of rat brain
30. The classification of seven transmembrane receptors in recombinant expression systems
31. Dynamic observation of dopamine autoreceptor effects in rat striatal slices
32. 2 short isoform in dopaminergic pathways
33. Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection
34. 2L receptortransfected MN9D cells and pituitary lactotrophs
35. 1 dopamine receptor agonist
36. 2 dopamine receptors
37. 3 receptor mutant mice
38. 3 receptor binding affinities
39. Dispersion in flow injection analysis measured with microvoltammetric electrodes
40. 2 receptor-deficient mice
41. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
42. 2 dopamine receptor mRNA
43. 1 dopamine receptor gene
44. A three-state receptor model of agonist action
45. i2 in GH4C1 pituitary cells
46. 3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms
47. 2+ currents in rat anterior pituitary cells
48. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist
49. Protein measurement with the Folin phenol reagent
50. Efficacy and potency comparisons among aporphine enantiomers: Effects on dopamine neurons in substantia nigra of rat
51. 3 receptors
52. Relationship between receptor occupancy and response at striatal dopamine autoreceptors
53. 2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP
54. 2 receptors and G-proteins
55. 125I]SCH 23982 in adjacent brain sections
56. 1 dopamine receptor agonist
57. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis
58. αi1, leading to the inhibition of adenylate cyclase in transfected cell lines
59. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum
60. 3 receptors
61. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems
62. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: Relation between displacement by dopamine againsts and their pharmacological effects
63. 1 receptor selectivity and comparisons to the partial agonist SKF 38393
64. 1-like dopamine receptor
65. 2 receptor agonists and antagonists
66. 2 post-synaptic receptor agonist
67. 2 receptor mRNA splice variants in the rat by solution hybridization/protection assay
68. 3) as a target for neuroleptics
69. Differential signal transduction by five splice variants of the PACAP receptor
70. +-stimulated release of acetylcholine from rat neostriatum
71. Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase
72. 2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems
73. 1 receptors: Efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents
74. 1 dopamine receptor agonists
75. 3 receptor ligands
76. 2 dopamine receptor mRNA in rat brain
77. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy
78. 3H]dopamine